文章预览
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC) Background Locally advanced unresectable or metastatic TNBC is highly aggressive and has a poor prognosis. Ivonescimab, a tetrameric bispecific antibody targeting PD-1 and VEGF, has the potential to produce complementary and synergistic anti-tumor effects through both pathways via cooperative binding. This study aimed to evaluate the safety and efficacy of ivonescimab in combination with chemotherapy in locally advanced unresectable or metastatic TNBC. Methods This was an open-label, multicenter phase II study in patients (pts) with locally advanced unresectable or metastatic TNBC. Pts received ivonescimab at 20 mg/kg Q2W and paclitaxel at 90 mg/m2 or nab-paclitaxel at 100 mg/m2 on the 1st, 8th, and 15th day of each four-week treatment cycle. The primary endpoints were safety and objective response rate (ORR) by RECIST1.1. The secondar
………………………………
